• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Treatment with indobufen of platelet hyperaggregation in a group of patients with vascular diseases].

作者信息

Barbieri U, Cappelli S, Zaniol P, Righi A, Artusi P, Scorrano M

机构信息

Servizio di Ematologia, Università di Modena.

出版信息

Minerva Med. 1991 Jan-Feb;82(1-2):63-7.

PMID:2000177
Abstract

Twenty-five patients with enhanced spontaneous platelet aggregation and impaired arterial or venous circulation syndromes have been treated by indobufen. Each of them received, by oral administration, 200 mg of the drug twice a day for periods of time from fifty one to hundred eleven days. This treatment normalized, in all the cases, the platelet aggregation. In eight patients of the group, three hours after the last drug administration, the average of the maximum platelet aggregation curves deflections, induced by ADP, epinephrine, ristocetin and collagen, resulted significantly reduced, while, in seven other patients, twelve hours after the last drug administration, only the aggregation curves induced by ADP and epinephrine resulted significantly inhibited. Most on the patients with arterial impairment syndromes noticed some improvements of their symptoms. Also the patients with light subjective post-phlebitic symptoms declared to feel better. The drug has been well tolerated. Therefore, its use is recommendable whenever it is advisable to get a full antiplatelet effect whose the prompt reversion might be required.

摘要

相似文献

1
[Treatment with indobufen of platelet hyperaggregation in a group of patients with vascular diseases].
Minerva Med. 1991 Jan-Feb;82(1-2):63-7.
2
[Chronic treatment of vascular diseases with indobufen].[吲哚布芬对血管疾病的长期治疗]
Minerva Cardioangiol. 1989 May;37(5):241-50.
3
Influence of indobufen on occlusion of arteriovenous fistulas and some platelet activity in intermittent peritoneal dialysis patients.吲哚布芬对间歇性腹膜透析患者动静脉内瘘闭塞及某些血小板活性的影响。
Pol J Pharmacol. 1996 May-Jun;48(3):327-9.
4
[Clinico-hematological evaluation of 57 patients undergoing antiaggregant treatment with indobufen].[57例接受吲哚布芬抗血小板治疗患者的临床血液学评估]
Recenti Prog Med. 1990 Jan;81(1):49-53.
5
[Heparan sulphate in association with indobufen in the treatment of chronic peripheral obliterative arteriopathy of the lower extremities. Controlled clinical trial].
Minerva Cardioangiol. 1998 Nov;46(11):457-69.
6
[Platelet aggregation inhibitory therapy in chronic arterial occlusive disease of the lower limbs: results of short-term clinico-instrumental study with indobufen].[吲哚布芬用于下肢慢性动脉闭塞性疾病的血小板聚集抑制治疗:短期临床器械研究结果]
Recenti Prog Med. 1989 Apr;80(4):204-7.
7
A prostacyclin-sparing effect of indobufen vs. aspirin.吲哚布芬与阿司匹林相比的前列环素保留效应。
Thromb Haemost. 1996 Mar;75(3):510-4.
8
An assessment of cardiopulmonary bypass-induced changes in platelet function using whole blood and classical light transmission aggregometry: the results of a pilot study.使用全血和经典光透射聚集法评估体外循环引起的血小板功能变化:一项初步研究的结果。
Anesth Analg. 2009 Jun;108(6):1747-54. doi: 10.1213/ane.0b013e3181a198ac.
9
[Effect of treatment with indobufen on blood viscosity indices and exercise tolerance in patients with coronary disease].吲哚布芬治疗对冠心病患者血液黏度指标及运动耐量的影响
Wiad Lek. 1993 Apr;46(7-8):245-9.
10
Effect of sarpogrelate, a 5-HT(2A) antagonist, on platelet aggregation in patients with ischemic stroke: clinical-pharmacological dose-response study.5-羟色胺(5-HT)2A拮抗剂沙格雷酯对缺血性中风患者血小板聚集的影响:临床药理学剂量反应研究
Cerebrovasc Dis. 2007;24(2-3):264-70. doi: 10.1159/000105135. Epub 2007 Jul 4.